[Spirapril in patients with hypertension: clinical experience in Germany].

Abstract

AIM:

To examine efficacy and tolerability of a single daily dose of 6 mg quadropril (spirapril).

MATERIAL AND METHODS:

An open multicenter study enrolled 5000 out-door patients with hypertension. All the patients received an ACE inhibitor quadropril for 3 months with four control visits (on week 0, 4, 8 and 12).

RESULTS:

Quadropril caused a marked decrease in systolic and diastolic blood pressure. At the end of the study 89.4% of patients had a systolic blood pressure reduction of at least 15 mm Hg and 85.4% had a diastolic blood pressure reduction of at least 10 mm Hg. There were no clinically significant heart rate changes. The overall tolerability of the drug was estimated as good or very good in 95.3% of patients. Only 2.9% of patients had side effects during treatment with once daily dose of 6 mg quadropril. No serious side effects were observed.

CONCLUSION:

6 mg daily dose of quadropril is an effective and safe therapy for arterial hypertension.

• Authors: J Schmidt, H Kraul
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 72 Issue 10 Pg. 90-4 ( 2000) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Primenenie spiraprila u patsientov s arterial'noĭ gipertonieĭ - klinicheskiĭ opyt v Germanii.
• PMID: 11220889 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Adrenergic beta-Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Calcium Channel Blockers
• Enalapril
• spirapril

Topics

• Administration, Oral
• Adrenergic beta-Antagonists (administration & dosage)
• Angiotensin-Converting Enzyme Inhibitors (administration & dosage)
• Blood Pressure (drug effects)
• Calcium Channel Blockers (administration & dosage)
• Drug Therapy, Combination
• Enalapril (administration & dosage, analogs & derivatives)
• Germany
• Humans
• Hypertension (drug therapy, physiopathology)
• Product Surveillance, Postmarketing
• Treatment Outcome